Neurocrine Biosciences Inc (NBIX) — Cash Flow-to-Debt Ratio
Neurocrine Biosciences Inc (NBIX) has a Cash Flow-to-Debt Ratio of 0.28x as of December 2025, meaning its operating cash flow of $388.40 Million could theoretically repay 0% of its total liabilities ($1.38 Billion) in one year. See Neurocrine Biosciences Inc (NBIX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Neurocrine Biosciences Inc Cash Flow-to-Debt Ratio (1996–2025)
Historical debt coverage capacity for Neurocrine Biosciences Inc across 30 annual periods. Also explore NBIX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Neurocrine Biosciences Inc (1996–2025)
Year-by-year debt coverage analysis for Neurocrine Biosciences Inc. For market capitalisation and broader financial context, see NBIX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.57x | $782.70 Million | $1.38 Billion | ▲ +7.7% |
| 2024 | 0.53x | $595.40 Million | $1.13 Billion | ▲ +37.9% |
| 2023 | 0.38x | $389.90 Million | $1.02 Billion | ▼ -25.5% |
| 2022 | 0.51x | $339.40 Million | $660.90 Million | ▲ +39.8% |
| 2021 | 0.37x | $256.50 Million | $698.50 Million | ▼ -2.2% |
| 2020 | 0.38x | $228.50 Million | $608.50 Million | ▲ +70.9% |
| 2019 | 0.22x | $147.00 Million | $669.10 Million | ▲ +11.0% |
| 2018 | 0.20x | $101.40 Million | $512.39 Million | ▲ +193.5% |
| 2017 | -0.21x | $-94.33 Million | $445.45 Million | ▲ +90.0% |
| 2016 | -2.11x | $-106.18 Million | $50.21 Million | ▼ -180.1% |
| 2015 | -0.75x | $-38.00 Million | $50.33 Million | ▲ +45.0% |
| 2014 | -1.37x | $-47.14 Million | $34.33 Million | ▼ -58.9% |
| 2013 | -0.86x | $-29.61 Million | $34.27 Million | ▼ -1.9% |
| 2012 | -0.85x | $-35.29 Million | $41.61 Million | ▼ -9414.1% |
| 2011 | -0.01x | $-698.00K | $78.29 Million | ▼ -102.2% |
| 2010 | 0.40x | $49.94 Million | $125.08 Million | ▲ +150.3% |
| 2009 | -0.79x | $-53.09 Million | $66.86 Million | ▲ +12.8% |
| 2008 | -0.91x | $-74.17 Million | $81.41 Million | ▼ -142.5% |
| 2007 | -0.38x | $-59.33 Million | $157.96 Million | ▲ +71.7% |
| 2006 | -1.33x | $-99.33 Million | $74.96 Million | ▼ -300.3% |
| 2005 | -0.33x | $-30.79 Million | $93.02 Million | ▲ +58.5% |
| 2004 | -0.80x | $-99.99 Million | $125.39 Million | ▼ -451.9% |
| 2003 | 0.23x | $37.13 Million | $163.84 Million | ▲ +112.1% |
| 2002 | -1.88x | $-79.36 Million | $42.28 Million | ▼ -208.8% |
| 2001 | -0.61x | $-21.86 Million | $35.96 Million | ▲ +25.8% |
| 2000 | -0.82x | $-18.64 Million | $22.75 Million | ▼ -1.8% |
| 1999 | -0.80x | $-10.30 Million | $12.80 Million | ▲ +36.1% |
| 1998 | -1.26x | $-10.70 Million | $8.50 Million | ▼ -199.6% |
| 1997 | 1.26x | $11.00 Million | $8.70 Million | ▼ -1.9% |
| 1996 | 1.29x | $6.70 Million | $5.20 Million | — |